Lilly shares jump on donanemab data despite ARIA deaths

The early signs were that markets were very impressed as they digested Eli Lilly’s (NYSE: LLY) data on its Alzheimer’s disease prospect, donanemab.

Shares in the US drug major were 4% higher in early trading on Wednesday after the firm presented positive results from the TRAILBLAZER-ALZ 2 Phase III study showing that donanemab significantly slowed cognitive and functional decline in early symptomatic Alzheimer's.

Donanemab met the primary endpoint of change from baseline until 18 months on the integrated Alzheimer's disease rating scale (iADRS).